CareFusion Corp.
Stryker may bid for Smith & Nephew following 6-month no-bid period | The week in medtech M&A
BD plans to use more cash, less debt for $12B CareFusion buy
CareFusion’s Q1 sales, earnings rise
CareFusion (NYSE:CFN) ended its last fiscal quarter as a public company on a strong note, posting earnings growth of 2.8% on a top-line gain of 11.1%.
Edwards Lifesciences is back in Wall Street’s good graces | Medtech Wall Street news for the week of October 6, 2014
AdvaMed in the age of consolidation
The winds of change in medtech are blowing in the Windy City.
As medtech’s best & brightest descended on Chicago for another annual confab at AdvaMed 2014, it was impossible to ignore that the industry has now entered the great age of consolidation with yet another multibillion-dollar healthcare deal.
Becton Dickinson to buy CareFusion for $12 billion in cash, stock
ConvaTec said to explore 2015 sale
FTC wants more data on MDT-COV deal | Medtech Wall Street news for the week of August 11, 2014
Strong Q4, $750M buyback give CareFusion a boost
CareFusion (NYSE:CFN) posted a stellar 4th-quarter, posting double-digit growth in revenues and earnings and beating Wall Street’s estimates.